Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.02 | 0.00 | -0.53 |
| FCF Yield | -4.84% | -6.70% | -14.40% | -6.23% |
| EV / EBITDA | -27.04 | -28.58 | -19.11 | 69.23 |
| Quality | ||||
| ROIC | -5.19% | -5.85% | -50.35% | -11.12% |
| Gross Margin | 41.36% | 36.93% | -978.15% | 25.64% |
| Cash Conversion Ratio | 0.49 | 0.70 | 0.10 | -12.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.03% | 2.22% | 4.36% | 6.28% |
| Free Cash Flow Growth | 25.30% | 50.59% | -56.34% | 27.78% |
| Safety | ||||
| Net Debt / EBITDA | -16.92 | -18.11 | -12.35 | 37.64 |
| Interest Coverage | -21.88 | -25.81 | -231.78 | -55.51 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.47 | 7.42 | 0.50 |
| Cash Conversion Cycle | 218.58 | 212.17 | 85.64 | 193.27 |